GenAdam Therapeutics

GenAdam Therapeutics was a private U.S. oncology biotech focused on developing therapeutics designed to induce anti-tumor immune responses and directly kill tumor cells by activating pyroptosis pathways. Publicly available information suggests the company operated in stealth mode and remained at a preclinical stage, with no clearly disclosed named clinical assets or human trial activity. Patent-related disclosures indicate interest in compositions and assays for identifying compounds or gene products relevant to cancers characterized by interruption of pyroptosis, as well as certain infectious diseases. Recent company-profile sources characterize the business as deadpooled/inactive rather than an operating biotech with an active pipeline.